The Regional Ethical Review Board (EPN) in Stockholm decided to approve the request to start clinical test for Dosell as a medical product.
The approval from EPN implies that Dosell, a patented digital drug dispenser for modern home-based health-care, can now be fully tested on patients. The tests will, as previously announced, be performed in collaboration with Apoteket.
MediRätt CEO Carl Johan Merner comments on EPN's approval:
- The Ethical Review Board approves any clinical tests on humans in Sweden. The decision by EPN is an important milestone for MediRätt as a company. It is a reassurement of that Dosell meets the highest standards as a medical device. I am very pleased that we are now ready to take the next step in our product development work in accordance with our timeplane and advance into further product refinement and, eventually, market launch.
For further information, please contact CEO Carl Johan Merner:
Mangold Fondkommission AB, tel: +46 8 5030 1550, is the Company's Certified Adviser.
This information is such that MediRätt is obligated to publish it in accordance with the EU's market abuse regulations. This information was submitted by the above contact person for publication on July 31, 2017 at 09:45 am CET.
The following documents can be retrieved from beQuoted
MediRatt Pressrelease 2017-07-31 English.pdf
MediRätt in brief
An average of eight elderly people die, and a further 500 are admitted to hospital in Sweden every day due to drug side effects, even though a solution to the problem exists. This is also a serious issue worldwide. MediRätt's business concept is to develop and market products that support more qualitative and safer healthcare in the home on the Swedish and international market. The Company has developed MediKoll and Dosell, which together form a unique overarching concept that ensure the elderly receive reliable and safe medication.